Rocalcitol YD

Rocalcitol YD Uses, Dosage, Side Effects, Food Interaction and all others data.

Rocalcitol YD is one of the most important active metabolites of vitamin D3. It is normally formed in the kidney from its precursor, 25-hydroxycolecalciferol (25-HCC). Physiological daily production is normally 0.5-1.0 mcg and is somewhat higher during periods of increased bone synthesis (e.g. growth or pregnancy). Rocalcitol YD promotes intestinal absorption of Calcium and regulates bone mineralization.

Rocalcitol YD is a biologically active calcitrophic hormone with anti-osteoporotic, immunomodulatory, anticarcinogenic, antipsoriatic, antioxidant, and mood-modulatory activities. Its main sites of action are the intestine, bone, kidney and parathyroid hormone . Rocalcitol YD is a ligand for the vitamin D nuclear receptor, which is expressed in, but not limited to, gastrointestinal (GI) tissues, bones, and kidneys . As an active form of vitamin D3, calcitriol elevates the plasma levels of calcium by stimulating intestinal calcium uptake, increasing reabsorption of calcium by the kidneys, and possibly increasing the release of calcium from skeletal stores. The duration of pharmacologic activity of a single dose of exogenous calcitriol is expected to be about 3 to 5 days .

In addition to its important role in calcium metabolism, other pharmacological effects of calcitriol have been studied in various conditions including cancer models. Various studies demonstrated expression of vitamin D receptors in cancer cell lines, including mouse myeloid leukemia cells . Rocalcitol YD has been found to induce differentiation and/or inhibit cell proliferation in vitro and in vivo in many cell types, such as malignant cell lines carcinomas of the breast, prostate, colon, skin, and brain, myeloid leukemia cells, and others . In early human prostate cancer trials, administration of 1.5 µg/d calcitriol in male participants resulted in a reduction in the rate of PSA rise in most participants, however it was coincided with dose-limiting hypercalcemia in most participants . Hypercalcemia and hypercalcuria were evident in numerous initial trials, and this may be due to these trials not testing the drug at concentrations that are active in preclinical systems . Findings from preclinical data show an additive or synergistic antineoplastic action of calcitriol when combined with agents including dexamethasone, retinoids, and radiation, as well as several cytotoxic chemotherapy drugs such as platinum compounds .

Vitamin D deficiency has long been suspected to increase the susceptibility to tuberculosis. The active form of calcitriol, 1,25-(OH)2-D3, has been found to enhance the ability of mononuclear phagocytes to suppress the intracellular growth of Mycobacterium tuberculosis. 1,25-(OH)2-D3 has demonstrated beneficial effects in animal models of such autoimmune diseases as rheumatoid arthritis. Vitamin D appears to demonstrate both immune-enhancing and immunosuppressive effects.

Trade Name Rocalcitol YD
Availability Prescription only
Generic Calcitriol
Calcitriol Other Names 1-alpha-25-Dihydroxyvitamin D3, Calcitriol, Calcitriolum
Related Drugs ergocalciferol, calcium carbonate, Caltrate, Drisdol, calcium lactate, Rocaltrol, calcifediol, Calcidol
Type
Formula C27H44O3
Weight Average: 416.6365
Monoisotopic: 416.329045274
Protein binding

Calcitriol is approximately 99.9% bound in blood, mostly by an alpha-globulin vitamin D binding protein .

Groups Approved, Nutraceutical
Therapeutic Class Vitamin in bone formation, Vitamin-D preparations
Manufacturer
Available Country Japan
Last Updated: September 19, 2023 at 7:00 am
Rocalcitol YD
Rocalcitol YD

Uses

Rocalcitol YD is used for the correction of the abnormalities of Calcium and Phosphate metabolism in patients with renal osteodystrophy.

Rocalcitol YD is also used for the treatment of established post-menopausal osteoporosis, hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, vitamin D dependent rickets.

Rocalcitol YD is also used to associated treatment for these conditions: Hypocalcemia, Osteodystrophy, Psoriasis Vulgaris (Plaque Psoriasis), Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

How Rocalcitol YD works

The mechanism of action of calcitriol in the treatment of psoriasis is accounted for by their antiproliferative activity for keratinocytes and their stimulation of epidermal cell differentiation. The anticarcinogenic activity of the active form of Rocalcitol YD appears to be correlated with cellular vitamin D receptor (VDR) levels. Vitamin D receptors belong to the superfamily of steroid-hormone zinc-finger receptors. VDRs selectively bind 1,25-(OH)2-D3 and retinoic acid X receptor (RXR) to form a heterodimeric complex that interacts with specific DNA sequences known as vitamin D-responsive elements. VDRs are ligand-activated transcription factors. The receptors activate or repress the transcription of target genes upon binding their respective ligands. It is thought that the anticarcinogenic effect of Rocalcitol YD is mediated via VDRs in cancer cells. The immunomodulatory activity of calcitriol is thought to be mediated by vitamin D receptors (VDRs) which are expressed constitutively in monocytes but induced upon activation of T and B lymphocytes. 1,25-(OH)2-D3 has also been found to enhance the activity of some vitamin D-receptor positive immune cells and to enhance the sensitivity of certain target cells to various cytokines secreted by immune cells.

A study suggests that calcitriol plays an immunoregulatry role by suppressing the aryl hydrocarbon receptor (AhR) expression in human Th9, a pro-inflammatory CD4 T cell subset . This suppression subsequently leads to repressed expression of BATF, a transcription factor essential for Th9 . Rocalcitol YD has also been found to induce monocyte differentiation and to inhibit lymphocyte proliferation and production of cytokines, including interleukin IL-1 and IL-2, as well as to suppress immunoglobulin secretion by B lymphocytes.

Dosage

Rocalcitol YD dosage

Injection

The recommended intravenous initial dose of Rocalcitol YD injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals.

Capsule

Adult

Renal osteodystrophy: The initial daily dose is 0.25 mcg of Rocalcitol YD. In patients with normal or only slighty reduced Calcium level, doses of 0.25 mcg every other day are sufficient. If no satisfactory response in the biochemical parameters and clinical manifestations of the disease is observed within 2-4 weeks, the daily dosage may be increased by 0.25 mcg at 2-4 week intervals.

Post-menopausal osteoporosis: The recommended dose of Rocalcitol YD is 0.25 mcg twice daily.

Serum calcium and creatinin levels should be determined at 1-3 and 6 months and at 6 monthly intervals thereafter.

Hypoparathyroidism & Rickets: The recommended initial dose of Rocalcitol YD is 0.25 mcg per day in the morning. In patients with renal osteodystrophy or hypoparathyroidism and rickets if within 2-4 weeks no satisfactory response is observed by usual dose then dose may be increased at two to four week intervals.

Elderly patients

No specific dosage modifications are required in elderly patents.

Children

Dosage in children has not been established.

Side Effects

Since Rocalcitol YD exerts vitamin D activity, adverse effects may occur which are similar to those found when an excessive dose of vitamin D is taken, i.e. hypercalcaemia syndrome or calcium intoxication (depending on the severity and duration of hypercalcaemia). Occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation.

Toxicity

LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg .

Symptoms of calcitriol toxicity mirrors the early and late signs and symptoms of vitamin D intoxication associated with hypercalcemia . Early signs include weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Late signs are characterized by polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated SGOT and SGPT, ectopic calcification, hypertension, cardiac arrhythmias and, rarely, overt psychosis .

Precaution

Immobilised patients, e.g. those who have undergone surgery, are particularly exposed to the risk of hypercalcaemia. Patients with normal renal function who are taking Rocalcitol YD should avoid dehydration. Adequate fluid intake should be maintained.

Interaction

Concomitant treatment with a thiazide diuretic increases the risk of hypercalcaemia. Rocalcitol YD dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcaemia in such patients may precipitate cardiac arrhythmias. Administration of enzyme inducers such as phenytoin or phenobarbital may lead to increased metabolism and hence reduced serum concentrations of Rocalcitol YD. Therefore higher doses of Rocalcitol YD may be necessary if these drugs are administered simultaneously. Colestyramine can reduce intestinal absorption of fat-soluble vitamins and therefore may impair intestinal absorption of Rocalcitol YD.

Food Interaction

No interactions found.

Volume of Distribution

Upon intravenous administration, the volume of distribution of calcitriol was 0.49±0.14 L/kg in healthy male volunteers and 0.27±0.06 l/kg in uraemic male patients participating in a pharmacokinetic study . There is some evidence that calcitriol is transferred into human milk at low levels (ie, 2.2±0.1 pg/mL) in mothers . Rocalcitol YD from maternal circulation may also enter the fetal circulation .

Elimination Route

Upon administration, calcitriol is rapidly absorbed from the intestines. When a single oral dose of 0.5 mcg of calcitriol was administered, the mean serum concentrations of calcitriol rose from a baseline value of 40.0±4.4 (SD) pg/mL to 60.0±4.4 pg/mL at 2 hours, and declined to 53.0±6.9 at 4 hours, 50±7.0 at 8 hours, 44±4.6 at 12 hours and 41.5±5.1 at 24 hours . Following administration of single doses of 0.25 to 1.0 mcg of calcitriol, the peak plasma concentrations were reached within 3 to 6 hours . In a pharmacokinetic study, the oral bioavailability was 70.6±5.8% in healthy male volunteers and 72.2±4.8% in male patients with uraemia .

Half Life

After administration of single oral doses, the elimination half life was 5-8 hours .

Clearance

The metabolic clearance rate was 23.5±4.34 ml/min in healthy male volunteers and 10.1±1.35 ml/min in male patients with uraemia . In the pediatric patients undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months, the clearance rate was 15.3 mL/hr/kg .

Elimination Route

In normal subjects, approximately 27% and 7% of the radioactivity appeared in the feces and urine, respectively, within 24 hours . Rocalcitol YD undergoes enterohepatic recycling and biliary excretion. The metabolites of calcitriol are excreted primarily in feces. Cumulative excretion of radioactivity on the sixth day following intravenous administration of radiolabeled calcitriol averaged 16% in urine and 49% in feces .

Pregnancy & Breastfeeding use

Pregnancy category C. Rocalcitol YD has been found to be teratogenic in rabbits. There are no adequate and well-controlled studies in pregnant women. Rocalcitol YD should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Contraindication

Rocalcitol YD is contraindicated in patients with known hypersensitivity to any of its ingredients. Rocalcitol YD is also contraindicated in all diseases associated with hypercalcemia.

Special Warning

Elderly patients: No specific dosage modifications are required in elderly patients.

Acute Overdose

Administration of Rocalcitol YD to patients in excess of their daily requirements can cause hypercalcaemia, hypercalciuria and hyperphospatemia. Since Rocalcitol YD is a derivative of vitamin D, the signs and symptoms of overdose are the same as for an overdose of vitamin D.

Storage Condition

Store between 15-30° C. Protect from moisture, heat and light. Do not freeze.

Innovators Monograph

You find simplified version here Rocalcitol YD

Rocalcitol YD contains Calcitriol see full prescribing information from innovator Rocalcitol YD Monograph, Rocalcitol YD MSDS, Rocalcitol YD FDA label

http://classyfire.wishartlab.com/tax_nodes/C0000000
http://classyfire.wishartlab.com/tax_nodes/C0000012
http://classyfire.wishartlab.com/tax_nodes/C0000258
http://classyfire.wishartlab.com/tax_nodes/C0001460
http://classyfire.wishartlab.com/tax_nodes/C0001460
http://classyfire.wishartlab.com/tax_nodes/C0001553
http://classyfire.wishartlab.com/tax_nodes/C0001670
http://classyfire.wishartlab.com/tax_nodes/C0001661
http://classyfire.wishartlab.com/tax_nodes/C0001292
http://classyfire.wishartlab.com/tax_nodes/C0004150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17823
http://www.genome.jp/dbget-bin/www_bget?cpd:C01673
http://www.lipidmaps.org/data/LMSDRecord.php?LMID=LMST03020258
http://www.hmdb.ca/metabolites/HMDB0001903
http://www.genome.jp/dbget-bin/www_bget?drug:D00129
http://www.genome.jp/dbget-bin/www_bget?cpd:C01673
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5280453
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508162
https://www.chemspider.com/Chemical-Structure.4444108.html
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50200182
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1894
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=17823
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL846
https://zinc.docking.org/substances/ZINC000100015048
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000289
http://www.pharmgkb.org/drug/PA448717
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779
https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VDX
http://www.rxlist.com/cgi/generic2/calcitri.htm
https://www.drugs.com/cdi/calcitriol.html
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/vit_0265.shtml
https://en.wikipedia.org/wiki/Calcitriol
*** Taking medicines without doctor's advice can cause long-term problems.
Share